38 results about "Retinal neovascularization" patented technology

The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors.

The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and / or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

A photosensitive tetrapyrrole derivative having formula (I)where n stands for 1 or 2 or a pharmaceutically acceptable salt thereof is useful as an effective ingredient in an obstruent composition for photochemotherapeutically obstructing neovascular vessels. The photosensitive tetrapyrroles of the formula (I) may be administered in a photochemotherapeutic method for obstructing neovascular vessels, particularly choroidal and retinal neovascularizations.

Methods of regulating angiogenesis, ischemic injury and / or wound healing by modulating the activity of leptin, particularly as mediated by the leptin receptor, and / or the interaction between leptin and the leptin receptor. Correspondingly, these methods can also be used to treat diseases mediated by angiogenesis, including wound healing, tumors and tumor metastasis, diabetic microangiopathy, retinal neovascularization, neovascularization of adipose tissue and fat metabolism, revascularization of necrotic tissue, enhancement or vascularization in microvascular transplants, and ovarian follicle maturation. Assays for identifying agents that modulate leptin and / or leptin receptor-mediated angiogenesis and / or wound healing and their use in treating angiogenesis-mediated diseases or conditions involving wound healing are also disclosed.

Methods and compositions for the prophylactic and therapeutic treatment of retinal disorders associated with neovascularization using topical ophthalmic compositions comprising hydroxamic acid matrix metalloproteinase inhibitors such as batimastat.

The invention discloses a method for constructing a disease model on the basis of a gene operation strategy and application, and relates to the technical field of biology. According to the method, anEmc3 gene is prevented from being expressed in vascular endothelial cells or cerebellum Purkinje cells of a target animal through a gene operation technology. By using the method, a disease animal model showing typical characteristics of retinal neovascularization diseases or cerebellar ataxia diseases can be obtained. The method provides a new thought or strategy for constructing a retinal neovascularization disease model or a cerebellar ataxia disease model. In addition, the disease model obtained by means of the method also provides a model basis for science researchers to study the retinalneovascularization diseases and screen medicines for treating the retinal neovascularization diseases or the cerebellar ataxia diseases.

Methods and compositions for treating ophthalmic disease and reducing retinal neovascularization using progenitor cells, such as postpartum-derived cells, and conditioned media produced from the cells, are disclosed.

The invention discloses a method for constructing a retinal neovascularization disease animal model by using a gene manipulation technology, a cultivation method and application, and relates to the technical field of gene editing. According to the construction method disclosed by the invention, the Ctnnnd1 gene in the vascular endothelial cells of the target animal is not expressed or the expression of the Ctnnd1 gene is inhibited by utilizing a gene manipulation technology. By means of the method, the animal model of the retinal neovascularization disease can be obtained, the variety of the animal model of the retinal neovascularization disease is enriched, more diversified model selections are provided for related research of the retinal neovascularization disease, and scientific research of the retinal neovascularization disease, development of related treatment drugs and the like are promoted.

Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.

The invention discloses a retinal angiomatous proliferation (RAP) and / or retinal capillary hemangioma (RCH) mouse model; the model is a gene knockout mouse obtained by crossing a Cre mouse, a Rb floxed mouse and a Vhl floxed mouse.A large number of new blood vessels exist on the peripheral retina of an Rb / Vhl double knockout (DKO) mouse model, the blood vessels penetrate an entire layer, and a dense capillary network is formed and the normal layered structure of a retinal three-layer capillary network is lost.The phenotypes are more severe than the retinal neovascularization in an RAP model inthe prior art; some new blood vessels still exist on the peripheral retina of Rb / P107 / Vhl triple knockout (TKO) mice, but significant phase III RAP and RCH lesions are formed under the retina.

Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD, containing a photosensitizer and a targeting molecule such as factor VII (“fVII”), fVIIa, or modified fVII, which binds with high affinity and specificity to tissue factor (TF). TF is more highly expressed, abnormally expressed or specifically expressed on endothelial cells lining the luminal surface of pathological neovasculature, than on normal vasculature, thus providing a specific and accessible therapeutic target. Following administration of fVIIPD, the compound specifically binds to the pathological neovasculature of the eye by interaction of the targeting molecule with TF expressed by endothelial cells within abnormal blood vessels. The photosensitizer may then be activated with a non-thermal laser light for selective destruction of abnormal vasculature.

The invention discloses a construction method and application of a retinal vasculopathy model, and relates to the field of eye disease research. The Jup gene in vascular endothelial cells of a target animal is not expressed or is inhibited in expression through a genetic engineering technique, so that the target animal shows typical retinal neovascularization disease characteristics. The target animal can be used as a retinal neovascularization disease model for research of the retinal neovascularization disease, can also help to clarify the pathogenesis process and mechanism of the retinal neovascularization disease and enrich the theoretical basis of retinal neovascularization, and provides a new target for treatment or prevention of the retinal neovascularization disease to assist research and development of retina neovascularization treatment means.

The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and / or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.

The invention discloses a retinal neovascularization detection method for a color fundus image. The method comprises the steps of obtaining color fundus image data and performing preprocessing to obtain training data; constructing a deep learning network model for retinal neovascularization detection; training the deep learning network model by adopting the training data to obtain a retinal neovascularization detector; preprocessing the color fundus image data to be detected; adopting a retinal neovascularization detector to detect the preprocessed to-be-detected color eye fundus image data toobtain a prediction probability graph of pixels judged as retinal neovascularization in the to-be-detected color eye fundus image; and carrying out thresholding processing to obtain a final detectionresult of the retinal neovascularization in the to-be-detected color fundus image. The invention further discloses an imaging method comprising the retinal neovascularization detection method for thecolor fundus picture. The device is high in reliability, good in practicability and good in detection effect.

The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and / or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or angiogenesis, iris neovascularization or angiogenesis, retinal neovascularization or angiogenesis, diabetic proliferative retinopathy and non-diabetic proliferative retinopathy.

The invention belongs to the technical field of diabetic animal model construction, and particularly relates to a method for constructing a ZDF (Zucker diabetic fatty) rat model for proliferative diabetic retinopathy (PDR). The method for constructing the model with PDR comprises the following steps: carrying out high-fat and high-sugar diet feeding on ZDF rats, and inducing hyperglycemia formation and dyslipidemia to obtain the rat model for PDR. Experiments find that the rat model obtained by the method can be successfully constructed, the obtained model has obviously increased blood sugar, abnormal lipid metabolism, retinal neovascularization indicated by fundus angiography FFA, vitreous opacity, retinal inner layer thinning indicated by OCT, retinal inner layer thinning indicated by pathology, remarkable reduction of ganglion cells and alteration of garland-like loss of the outer nuclear layer, the modeling time is short, and the application prospect is excellent.

The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and / or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.

The invention belongs to the technical field of traditional Chinese medicine, in particular to traditional Chinese medicine for treating proliferative diabetic retinopathy. The traditional Chinese medicine comprises, by weight, 5-13 parts of American ginseng, 8-16 parts of radix pseudostellariae, 8-16 parts of atractylodes macrocephala koidz, 11-15 parts of Chinese yam, 8-16 parts of prepared rehmannia roots, 8-16 parts of fruits of Chinese wolfberry, 8-16 parts of glossy privet fruits, 8-16 parts of seeds of Chinese dodder, 5-13 parts of ligusticum wallichii, 5-13 parts of corydalis tuber, 8-16 parts of salviae miltiorrhizae, 5-13 parts of Rhizoma Sparganii, 1-3 parts of leeches, 5-13 parts of rhizoma arisaematis, 2-4 parts of rhizoma typhonii, 8-16 parts of semen cassiae and 8-16 parts of seeds of feather cockscomb. The traditional Chinese medicine can effectively reduce the intraocular pressure and the thickness of yellow spots of an affected eye, reduce the leakage area of retinal neovascularization, promote retinal neovascularization to gradually vanish, improve the vision of a patient and improve the life quality of the patient.

Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.

The invention discloses a method for inducing retinal and choroidal neovascularization by AAV-VEGF (adeno-associated virus transduced-vascular endothelial growth factor), and the AAV-VEGF is applied to the animal body by a subretinal injection method. Through the way, according to the method for inducing the retinal and choroidal neovascularization by the AAV-VEGF, by subretinal injection of AAV-VEGF gene, retinal neovascularization hyperplasia can be promoted, meanwhile the retinal neovascularization induced by the AAV-VEGF can be maintained for a long term, the successful rate can reach over 98%, and diabetic fundus lesions or wet age-related maculopathy simulated retinopathy can be obtained.

The invention discloses a construction method and application of a retinal neovascularization disease model, and relates to the field of biotechnology. The construction method knocks out the Tmem30a gene sequence in the genome of the target animal vascular endothelial cells, so that the target animal exhibits the typical retinal neovascularization disease characteristics. The target animal can beused as a model of retinal neovascularization disease, which can help to clarify the pathogenesis and mechanism of retinal neovascularization disease, and provide a new target for the treatment or prevention of retinal neovascularization disease.

Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.

The invention discloses a derivative containing nitrogen heterocyclic rings and application of the derivative in retinal neovascularization diseases. The derivative has the biological structural formula shown in the description, wherein R1, R2, R3 and R4 are respectively and independently selected from -H or -CN. Under the same concentration of 5microg / mL, the growth inhibition ratios of the embodiment II, the embodiment III and the embodiment IV to HRCEC are superior to a monoclonal antibody drug Avastin. By injecting the compound into a vitreous body, the formation of pathologic new vesselscan be reduced, so that the derivative of the formula I or the salt of the derivative can be used for deeply researching and developing retinal neovascularization relevant diseases such as retinal vein occlusion, proliferative diabetic retinopathy, subretinal neovascular membrane, neovascular glaucoma, retinopathy of prematurity and proliferative vitreoretinopathy.

The invention discloses a medicine for treating diabetic angiopathy. The medicine comprises an orally taken medicine and an externally applied medicine; the orally taken medicine comprises Radix Ginseng, Bulbus Lilii, Rhizoma disporopsis pernyi, Ganoderma Lucidum Karst, Thallus Porphyrae, Radix Codonopsis lanceolatae, Herba Urariae crinitae, Radix Oenotherae erythrosepalae oil, Radix Tiliae, Plantula Brassicae chinensis, Folium Ilicis Cornutae and Radix Glycyrrhizae; and the externally applied medicine comprises Radix Angelicae Sinensis, Radix Ginseng, Ganoderma Lucidum Karst, Fructus syzygii cumini, Fructus Lycii and Radix Glycyrrhizae. The medicine has the beneficial effect that the medicine comprises the orally taken medicine and the externally applied medicine, the orally taken medicine and the externally applied medicine are used jointly and interwork, the medicine takes effect quickly and is good in effect when used for clinically treating diabetic retinopathy caused by deficiency of both Qi and Yin, eye pressure can be relieved effectively, retinal neovascularization is reduced effectively, vision of a patient is improved, living quality of the patient is improved, meanwhile, the medicine is high in safety and does not have toxic or side effects, and the disease is difficult to recur.

Pathological retinal neovascularization is a common micro-vascular complication in several retinal diseases including retinopathy of prematurity (ROP), diabetic retinopathy, age-related macular degeneration and central vein occlusion. Disclosed herein are compositions and methods useful for the treatment or prevention of retinal neovascularization and related diseases in a subject in need thereof. Exemplary methods include administering a composition including PEGylated arginase 1 to a subject in need thereof to promote reparative angiogenesis and decrease retinal neovascularization in the eye.

Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and / or conditions involving inflammation and / or angiogenesis, particularly ocular diseases and / or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.